Nonclassical biosynthetic pathway allows bacteria to synthesize tocopherol

Microbial production of tocopherols—key forms of vitamin E used in healthcare, medicine, and animal nutrition—has long been limited by incomplete biosynthetic compatibility with industrial fermentation. Now, researchers report a bacterial strategy that sidesteps the familiar “classical” α-tocopherol route, offering an alternative blueprint for scalable manufacture. The work focuses on Rhodobacter species, where tocopherol formation can proceed through an atypical sequence of intermediates.

Instead of relying on the classical requirement for 2,3-dimethyl-5-phytyl-1,4-benzoquinone (DMPBQ), the team describes a non-classical pathway that bypasses this step entirely. Such a detour is significant because it reduces dependence on intermediate chemistry that has historically acted as a bottleneck in microbial engineering.

At the center of the study is a Rhodobacter methyltransferase carrying unusual “bifunctional” capabilities. This enzyme exhibits both γ- and β-tocopherol methyltransferase activities, enabling a direct conversion toward α-tocopherol. In biochemical terms, the enzyme effectively repurposes substrate flow so that δ-tocopherol and related tocopherol intermediates can be advanced toward the vitamin E form most commonly valued commercially.

The researchers also identify a role for geranylgeranyl pyrophosphate reductase (GR) in transforming tocotrienols into tocopherols. This reduction step helps convert related lipid precursors into the tocopherol spectrum, aligning production outputs with target compounds rather than leaving the pathway stranded on tocotrienol branches.

To validate and enhance performance, the group applies systematic metabolic engineering in Rhodobacter sphaeroides. By tuning pathway components and fermentation conditions, they demonstrate substantial accumulation of tocopherols in culture.

In shake flasks, the engineered strain reaches a total tocopherol titer of 508.21 mg l⁻¹. Further process optimization during fed-batch fermentation increases production to 3.51 g l⁻¹, a level that moves bacterial synthesis closer to industrial relevance.

Taken together, the study presents a bacteria-native, non-classical biosynthetic route that avoids the DMPBQ-centric classical pathway. Beyond its yield gains, the mechanistic clarity—methyltransferase bifunctionality and GR-mediated conversion—offers actionable targets for future strain optimization.

With microbial fermentation now producing gram-per-liter tocopherols via a redesigned metabolic logic, the findings could accelerate commercial vitamin E production and expand the feasible routes for engineering lipid-derived bioactives.